ArticleInternational journal of surgery case reports2026
Ten-year recurrence-free survival in stage IV perforated appendiceal mucinous adenocarcinoma with high-risk features: a case report.
Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Appendiceal mucinous adenocarcinoma (MAC) associated with pseudomyxoma peritonei (PMP) has a poor prognosis in advanced stages. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is generally regarded as the standard treatment for PMP, but its management may require individualization based on tumor burden, histopathological risk, the patient's condition, and available treatment options. Presentation of the case: A 71-year-old man was initially managed conservatively for suspected acute appendicitis and was later referred to our department because of persistent appendiceal enlargement. Before the planned outpatient evaluation, he developed perforated appendicitis and underwent emergency laparoscopic appendectomy. Pathological examination showed MAC with high-risk features and a positive surgical margin. After multidisciplinary discussion, additional surgery aimed at macroscopic disease reduction was performed without CRS/HIPEC, including right hemicolectomy, lymph node dissection, and resection of visible peritoneal nodules and a paracaval lymph node. Postoperative FDG-PET/CT suggested residual pelvic disease, and systemic chemotherapy with capecitabine, oxaliplatin, and bevacizumab was administered. A clinical complete response was achieved, and the patient has remained recurrence-free for 10 years. Clinical discussion: This case suggests that long-term recurrence-free survival may be possible when the biologically active tumor burden is limited, timely surgery achieves substantial macroscopic disease reduction, and effective systemic chemotherapy controls residual disease, even if CRS/HIPEC is not performed. Conclusion: Long-term RFS may be achievable in carefully selected patients with stage IV appendiceal MAC and PMP, even without CRS/HIPEC. This case does not challenge CRS/HIPEC as the standard strategy for PMP but supports individualized multidisciplinary decision-making when CRS/HIPEC is not feasible or not selected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.